Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study
Name:
35668384.pdf
Size:
1.368Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Waddell, ThomasFife, K.
Griffiths, R.
Sharma, A.
Dhokia, P.
Groves, L.
Hurst, M.
Tsang, C.
Sugrue, D.
McKenna, S.
Houghton, J.
Carroll, R.
Affiliation
Gastro-Oesophageal and Renal Unit, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2022
Metadata
Show full item recordAbstract
Background: The CheckMate 025 trial established nivolumab monotherapy as one of the standards of care in previously treated advanced or metastatic renal cell carcinoma (aRCC). However, supporting real-world data is lacking. This study investigated characteristics, treatment sequences and clinical outcomes of patients who received nivolumab monotherapy for previously treated aRCC in the UK. Methods: This was a retrospective cohort study of aRCC patients treated with nivolumab at second line or later (2L +) at 4 UK oncology centres. Eligible patients commenced nivolumab (index date) between 01 March 2016 and 30 June 2018 (index period). Study data were extracted from medical records using an electronic case report form. Data cut-off (end of follow-up) was 31 May 2019. Results: In total, 151 patients were included with median follow-up of 15.2 months. Mean age was 66.9 years, male preponderance (72.2%), and mostly Eastern Cooperative Oncology Group performance status grade 0-1 (71.5%). Amongst 112 patients with a known International Metastatic RCC Database Consortium score, distribution between favourable, intermediate, and poor risk categories was 20.5%, 53.6%, and 25.9% respectively. The majority of patients (n = 109; 72.2%) received nivolumab at 2L, and these patients had a median overall survival (OS) of 23.0 months [95% confidence interval: 17.2, not reached]. All patients who received nivolumab at 2L had received TKIs at 1L. Amongst the 42 patients (27.8%) who received nivolumab in third line or later (3L +) the median OS was 12.4 months [95% CI: 8.8, 23.2]. The most common reasons for nivolumab discontinuation were disease progression (2L: 61.2%; 3L: 68.8%) and adverse events (2L: 34.7%; 3L: 28.1%). Conclusion: This study provides real-world evidence on the characteristics, treatment sequences, and outcomes of aRCC patients who received 2L + nivolumab monotherapy in the UK. Nivolumab-specific survival outcomes were similar to those achieved in the CheckMate 025 trial.Citation
Waddell T, Fife K, Griffiths R, Sharma A, Dhokia P, Groves L, et al. Real-world treatment sequencing and survival in previously treated advanced renal cell carcinoma patients receiving nivolumab monotherapy: a UK retrospective cohort study. Vol. 22, BMC Cancer. Springer Science and Business Media LLC; 2022.Journal
BMC CancerDOI
10.1186/s12885-022-09694-yPubMed ID
35668384Additional Links
https://dx.doi.org/10.1186/s12885-022-09694-yType
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1186/s12885-022-09694-y
Scopus Count
Collections
Related articles
- Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma after Prior Therapy: Interim Results from the Noninterventional NORA Study.
- Authors: Grimm MO, Grünwald V, Müller-Huesmann H, Ivanyi P, Schostak M, von der Heyde E, Schultze-Seemann W, Belz H, Bögemann M, Wang M, Herber M, Bedke J, NORA Study Group
- Issue date: 2022 Sep
- Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
- Authors: Motzer RJ, Escudier B, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Plimack ER, Procopio G, McDermott DF, Castellano D, Choueiri TK, Donskov F, Gurney H, Oudard S, Richardet M, Peltola K, Alva AS, Carducci M, Wagstaff J, Chevreau C, Fukasawa S, Tomita Y, Gauler TC, Kollmannsberger CK, Schutz FA, Larkin J, Cella D, McHenry MB, Saggi SS, Tannir NM
- Issue date: 2020 Sep 15
- A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data.
- Authors: Hinata N, Yonese J, Masui S, Nakai Y, Shirotake S, Tatsugami K, Inamoto T, Nozawa M, Ueda K, Etsunaga T, Osawa T, Uemura M, Kimura G, Numakura K, Yamana K, Miyake H, Fukasawa S, Ochi K, Kaneko H, Uemura H
- Issue date: 2020 Aug
- Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma.
- Authors: Cao X, Tang D, Ratto B, Poole A, Ravichandran S, Jin L, Gao W, Swallow E, Vogelzang NJ
- Issue date: 2020 Feb
- Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up.
- Authors: Tomita Y, Kondo T, Kimura G, Inoue T, Wakumoto Y, Yao M, Sugiyama T, Oya M, Fujii Y, Obara W, Motzer RJ, Uemura H
- Issue date: 2020 Jan 24